

November 03, 2016

The National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex, Bandra (E)
Mumbai - 400051

The Bombay Stock Exchange Limited
15th Floor, Phiroze Jeejeeboy Towers
Dalal Street,
Mumbai - 400001

Subject: Unaudited Financial Results for the quarter and half year ended September 30, 2016

Ref: Regulation 30 & 33 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations 2015 (hereinafter referred as Listing Regulations)

Dear Sir/Madam,

Please take note that the Board of Directors in their meeting held today i.e. November 03, 2016 approved the unaudited Financial Results (Standalone and Consolidated) of the Company for the Quarter and half year ended September 30, 2016.

A copy of the Results along with Limited Review Report issued by the Statutory Auditors M/s S. R. Batliboi & Co., LLP on such financials is attached herewith.

The Board Meeting commenced at 11:30 AM and concluded at 2:00 PM.

We request you to please take the same on record.

Thanking You,

Yours Faithfully,

For **Dr. Lal PathLabs Limited**



Rajat Kalra
Company Secretary & Legal Head
Encl: As above

**Review Report to
The Board of Directors
Dr. Lal PathLabs Limited**

1. We have reviewed the accompanying statement of unaudited financial results of Dr. Lal PathLabs Limited ('the Company') for the quarter and six months ended September 30, 2016 (the "Statement"). This Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.
4. We report that the accompanying unaudited financial results for the corresponding three months ended September 30, 2015 have been taken based on the management certified accounts and have not subjected to any review by us.

For S.R. BATLIBOI & CO. LLP**ICAI Firm registration number: 301003E/E300005**

Chartered Accountants

per Anil Gupta

Partner

Membership No. : 87921

Place: New Delhi

Date: November 3, 2016



STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED 30th SEPTEMBER 2016

(Rs. In Lacs)


S. No.	Particulars	3 Months Ended 30.09.2016	Preceding 3 Months Ended 30.06.2016	Corresponding 3 Months Ended 30.09.2015	Year to date figures for current period ended 30.09.2016	Year to date figures for previous period ended 30.09.2015	Year Ended 31.03.2016
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Audited)
1.	Income from Operations						
	(a) Net sales/Income from operations	25,291	21,565	20,898	46,856	39,204	76,534
	(b) Other Operating income	1	1	2	2	4	6
	Total income from Operations (net)	25,292	21,566	20,900	46,858	39,208	76,540
2.	Expenses						
	(a) Cost of materials consumed	5,795	4,712	4,740	10,507	8,583	16,813
	(b) Employee benefits expense						
	i.) ESOP Cost	-	-	2,166	-	2,391	(347)
	ii.) ESPP/RSU Cost	195	60	145	255	240	435
	iii.) Others	3,891	3,598	3,362	7,489	6,433	13,218
	(c) Depreciation and amortization expense	771	743	809	1,514	1,549	3,201
	(d) Other Expenses						
	i.) Fees to collection centres	2,488	2,160	1,983	4,648	3,690	7,383
	ii.) Other Expenses	5,188	5,203	4,970	10,391	9,592	18,652
	Total Expenses	18,328	16,476	18,175	34,804	32,478	59,356
3.	Profit from operations before other income, finance costs and exceptional items (1-2)	6,964	5,090	2,725	12,054	6,730	17,184
4.	Other Income	750	584	498	1,334	904	2,041
5.	Profit from ordinary activities before finance costs, exceptional items (3 + 4)	7,714	5,674	3,223	13,388	7,634	19,225
6.	Finance Costs	-	1	15	1	18	49
7.i	Profit from ordinary activities after finance costs but before exceptional items (5 - 6)	7,714	5,673	3,208	13,387	7,616	19,176
7.ii	Profit from ordinary activities before tax (7.i + 2.b.i) (Before considering the ESOP cost)	7,714	5,673	5,374	13,387	10,007	18,829
8.	Exceptional Items	-	-	1,663	-	1,663	-
9	Profit from ordinary activities before tax (7.i - 8)	7,714	5,673	1,545	13,387	5,953	19,176
10.	Tax Expense	2,571	1,918	1,085	4,489	2,620	6,600
11.	Net Profit from ordinary activities after tax (9 - 10)	5,143	3,755	460	8,898	3,333	12,576
12.	Extraordinary items	-	-	-	-	-	-
13.	Net Profit for the period/year (11 - 12)	5,143	3,755	460	8,898	3,333	12,576
14	Paid-up equity share capital (Face value of Rs. 10/- each)	8,278	8,274	6,313	8,278	6,313	8,268
15	Paid-up preference share capital (Face value of Rs. 10/- each)	-	-	1,914	-	1,914	-
16	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-	-	39,584
17.i	Earning per share (before extraordinary items)						
	(of Rs. 10/- each) (not annualised)						
	(a) Basic	6.21	4.54	0.73	10.75	5.33	15.31
	(b) Diluted	6.17	4.51	0.55	10.68	4.03	15.20
17.ii	Earning per share (after extraordinary items)						
	(of Rs. 10/- each) (not annualised)						
	(a) Basic	6.21	4.54	0.73	10.75	5.33	15.31
	(b) Diluted	6.17	4.51	0.55	10.68	4.03	15.20

Statement of assets and liabilities		(Rs. In Lacs)	
Sl. No.	PARTICULARS	As at	As at
		30.09.2016	31.03.2016
		(Un audited)	(Audited)
A	EQUITY AND LIABILITIES		
1	Shareholders funds		
	a) Share capital	8,278	8,268
	b) Reserves and surplus	48,837	39,584
	Sub-total - Shareholders' funds	57,115	47,851
2	Share application money pending allotment	616	73
3	Non-current liabilities		
	a) Trade payables	1,045	983
	b) Other long term liabilities	1,518	1,368
	c) Long-term provisions	-	-
	Sub-total - Non current liabilities	2,563	2,351
4	Current liabilities		
	a) Trade payables	6,604	4,058
	b) Other current liabilities	1,126	1,741
	c) Short-term provisions	2,347	3,096
	Sub-total - Current liabilities	10,077	8,896
	TOTAL - EQUITY AND LIABILITIES	70,371	59,172
B	ASSETS		
1	Non-current assets		
	a) Fixed assets	13,837	13,388
	b) Non Current investments	2,790	1,159
	c) Deferred tax assets (net)	1,660	1,144
	d) Long-term loans and advances	1,762	1,554
	e) Other non-current assets	344	320
	Sub-total - Non-current assets	20,393	17,564
2	Current assets		
	a) Current investments	10,341	6,259
	b) Inventories	1,918	1,408
	c) Trade receivables	4,319	3,486
	d) Cash and bank balances	23,422	20,674
	e) Short-term loans and advances	8,887	9,120
	f) Other current assets	1,091	661
	Sub-total - Current assets	49,978	41,607
	TOTAL - ASSETS	70,371	59,172

Notes:

- The statutory auditors have performed the limited review of financial results for the Quarter & Half year ended as on September 30, 2016. The financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on November 03, 2016.
- During the current Quarter, the Company has Subscribed Equity Share Capital of NPR 400 Lacs (equivalent INR 250 Lacs) in its overseas wholly owned subsidiary - Dr Lal PathLabs Nepal Private Limited.
- Tax expenses are inclusive of/net off deferred tax charge/credit and tax adjustment for earlier years.
- As the Company is engaged in a single primary business segment, the disclosure requirement of Accounting Standard (AS 17) 'Segment Reporting' notified under Section 133 of the Companies Act 2013, read together with paragraph 7 of the Companies (Accounts) Rules, 2014 and the relevant provisions of the Companies Act, 2013 are not applicable.
- Previous year/period figures have been regrouped wherever considered necessary.

For and on behalf of the Board of Directors of Dr. Lal PathLabs Limited


(Hon'ble) Brig. Dr. Arvind Lal
(Chairman & Managing Director)

Place: New Delhi
Date: 03rd November 2016

**Review Report to
The Board of Directors
Dr. Lal PathLabs Limited**

1. We have reviewed the accompanying statement of unaudited consolidated financial results of Dr. Lal PathLabs Limited Group comprising Dr. Lal PathLabs Limited ('the Company') and its subsidiaries (together, 'the Group'), for the quarter ended September 30, 2016 (the "Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. This Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. We did not review revenues of Rs. 280 Lacs (including Rs 146 lacs for the quarter ended September 30, 2016) for the six months ended September 30, 2016 and assets as on September 30, 2016 of Rs 459 lacs respectively, included in the accompanying unaudited consolidated financial results relating to 2 subsidiaries. The unaudited financial results for one of the subsidiaries has been reviewed by other auditor whose report have been furnished to us and for another subsidiary, financial results has been taken based on the management certified accounts. Our conclusion on the unaudited quarterly financial results, in so far as it relates to such subsidiaries is based solely on the report of the other auditor/ management accounts. Further, the accompanying unaudited consolidated financial results for the corresponding three months ended September 30, 2015 have been taken based on management certified accounts and have not been subjected to any review by us.
4. Based on our review conducted as above and on consideration of report of the other auditor on the unaudited separate quarterly financial results and on the other financial information of the component, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited consolidated financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S.R. BATLIBOI & CO. LLP

ICAI Firm registration number: 301003E/E300005

Chartered Accountants

Anil Gupta

per Anil Gupta

Partner

Membership No.: 87921

Place: New Delhi

Date: November 3, 2016





Dr. Lal PathLabs Limited
 Corporate Identity Number: L74899DL1995PLC065388
 Regd. Office: Block - E, Sector - 18, Rohini, New Delhi - 110085
 Corporate Office: 12th Floor, Tower B, SAS Tower, Medicity, Gurgaon - 122001
 Website: www.lalpathlabs.com
 Phone: +91 124 3016500 | Fax: +91 124 4234468
 Email: cs@lalpathlabs.com

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED 30th SEPTEMBER 2016

(Rs. in Lacs)


S. No.	Particulars	3 Months Ended 30.09.2016	Preceding 3 Months Ended 30.06.2016	Corresponding 3 Months Ended 30.09.2015	Year to date figures for current period ended 30.09.2016	Year to date figures for previous period ended 30.09.2015	Year Ended 31.03.2016
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Audited)
1.	Income from Operations						
	(a) Net sales/Income from operations	26,216	22,283	21,571	48,499	40,500	79,126
	(b) Other Operating income	1	1	2	2	4	6
	Total Income from Operations (net)	26,217	22,284	21,573	48,501	40,504	79,132
2.	Expenses						
	(a) Cost of materials consumed	5,962	4,838	4,858	10,800	8,811	17,292
	(b) Employee benefits expense						
	i.) ESOP Cost	-	-	2,166	-	2,391	(347)
	ii.) ESPS Cost	195	60	145	255	240	435
	iii.) Others	4,014	3,693	3,471	7,707	6,615	13,595
	(c) Depreciation and amortization expense	671	647	713	1,318	1,359	2,828
	(d) Other Expenses						
	i.) Fees to collection centres	2,489	2,161	1,983	4,650	3,694	7,388
	ii.) Other Expenses	5,575	5,492	5,318	11,067	10,200	19,796
	Total Expenses	18,906	16,891	18,654	35,797	33,310	60,988
3.	Profit from operations before other income, finance costs and exceptional items (1-2)	7,311	5,393	2,919	12,704	7,194	18,144
4.	Other Income	627	601	507	1,228	918	1,977
5.	Profit from ordinary activities before finance costs, exceptional items (3 + 4)	7,938	5,994	3,426	13,932	8,112	20,121
6.	Finance Costs	-	1	15	1	18	50
7.i	Profit from ordinary activities after finance costs but before exceptional items (5 - 6)	7,938	5,993	3,411	13,931	8,094	20,072
7.ii	Profit from ordinary activities before tax (7.i +2.b.i) (Before considering the ESOP cost)	7,938	5,993	5,577	13,931	10,485	19,725
8.	Exceptional Items	-	-	1,663	-	1,663	-
9	Profit from ordinary activities before tax (7.i - 8)	7,938	5,993	1,748	13,931	6,431	20,072
10.	Tax Expense	2,653	1,976	1,099	4,629	2,684	6,749
11.	Net Profit from ordinary activities after tax (9 - 10)	5,285	4,017	649	9,302	3,747	13,323
12.	Extraordinary items	-	-	-	-	-	-
13.	Net Profit for the period/year (11 - 12)	5,285	4,017	649	9,302	3,747	13,323
14.	Minority Interest	34	35	30	69	54	104
15.	Net Profit after taxes and minority interest (13 - 14)	5,251	3,982	619	9,233	3,693	13,219
16.	Paid-up equity share capital (Face value of Rs. 10/- each)	8,278	8,274	6,313	8,278	6,313	8,268
17.	Paid-up preference share capital (Face value of Rs. 10/- each)	-	-	1,914	-	1,914	-
18.	Reserves excluding Revaluation Reserves as per balance sheet						42,394
19.i	Earning per share (before extraordinary items) (of Rs. 10/- each) (not annualised):						
	(a) Basic	6.34	4.81	0.99	11.16	5.90	16.09
	(b) Diluted	6.30	4.78	0.75	11.08	4.47	15.98
19.ii	Earning per share (after extraordinary items) (of Rs. 10/- each) (not annualised):						
	(a) Basic	6.34	4.81	0.99	11.16	5.90	16.09
	(b) Diluted	6.30	4.78	0.75	11.08	4.47	15.98

Statement of assets and liabilities		(Rs. In Lacs)	
Sl. No.	PARTICULARS	As at	As at
		30.09.2016	31.03.2016
		(Un audited)	(Audited)
A	EQUITY AND LIABILITIES		
1	Shareholders funds		
	a) Share capital	8,278	8,268
	b) Reserves and surplus	51,950	42,394
	Sub-total - Shareholders' funds	60,228	50,662
2	Share application money pending allotment	616	73
3	Minority Interest	210	289
4	Non-current liabilities		
	a) Trade payables	1,089	1,023
	b) Other long term liabilities	1,526	1,378
	c) Long-term provisions	21	20
	Sub-total - Non current liabilities	2,636	2,421
5	Current liabilities		
	a) Trade payables	6,905	4,227
	b) Other current liabilities	1,144	1,755
	c) Short-term provisions	2,410	3,097
	Sub-total - Current liabilities	10,459	9,078
	TOTAL - EQUITY AND LIABILITIES	74,149	62,523
B	ASSETS		
1	Non-current assets		
	a) Goodwill (on consolidation)	5,445	4,172
	b) Fixed assets	13,472	12,801
	c) Deferred tax assets (net)	1,745	1,205
	d) Long-term loans and advances	1,800	1,591
	e) Other non-current assets	565	381
	Sub-total - Non-current assets	23,027	20,150
2	Current assets		
	a) Current investments	10,544	6,432
	b) Inventories	1,977	1,452
	c) Trade receivables	4,491	3,631
	d) Cash and bank balances	23,953	20,995
	e) Short-term loans and advances	9,065	9,199
	f) Other current assets	1,092	665
	Sub-total - Current assets	51,122	42,374
	TOTAL - ASSETS	74,149	62,523

Notes:

- The statutory auditors have performed the limited review of financial results for the Quarter & Half year ended September 30, 2016. The financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on November 03, 2016.
- The Consolidated Financial Results represents consolidated results of the Company and its subsidiaries.
- Tax expenses are inclusive of/net off deferred tax charge/credit and tax adjustment for earlier years.
- As the group's business is engaged in a single primary business segment, the disclosure requirement of Accounting Standard (AS 17) 'Segment Reporting' notified under Section 133 of the Companies Act 2013, read together with paragraph 7 of the Companies (Accounts) Rules, 2014 and the relevant provisions of the Companies Act, 2013 are not applicable.
- During the quarter, the Parent Company has Subscribed Equity Share Capital of NPR 400 Lacs (equivalent INR 250 Lacs) in its overseas wholly owned subsidiary - Dr Lal PathLabs Nepal Private Limited.
- Previous year/period figures have been regrouped wherever considered necessary.

For and on behalf of the Board of Directors of Dr. Lal PathLabs Limited



(Hon'ble) Brig. Dr. Arvind Lal
(Chairman & Managing Director)

Place : New Delhi
Date : 03rd November 2016